Biodesix vs Castle Biosciences
BDSX and CSTL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDSX and CSTL compare
Castle Biosciences is the larger company, worth 9.7 times as much as Biodesix ($1.0B against $107M).
Biodesix grew revenue faster over the last twelve months (31.2% versus 9.8% for Castle Biosciences).
Castle Biosciences keeps more of each dollar of sales as profit, with a net margin of −6.1% compared with −25.7% at Biodesix.
Castle Biosciences scores higher on the StockData Score (11 against 4 for Biodesix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDSX | CSTL |
|---|---|---|
| Size and price | ||
| Market cap | $107M | $1.0B |
| Share price | $10.12 | $33.99 |
| Change, 1 year | 34.2% | −2.2% |
| Change, 5 years | −92.1% | −28.4% |
| Beta (5Y) | 0.73 | 1.38 |
| Employees | 334 | 883 |
| StockData Score | ||
| Total score | 4 | 11 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.0× (better) | 2.8× |
| P/B | 12.3× | 2.2× (better) |
| P/FCF | – | 262× |
| FCF yield | −17.9% | 0.38% (better) |
| Fair value | – | $36.69 |
| Margin of safety | – | 7.4% |
| Growth | ||
| Revenue growth (TTM) | 31.2% (better) | 9.8% |
| Revenue growth, 5Y average | 14.2% | 40.6% (better) |
| Profitability | ||
| Gross margin | – | 77.1% |
| Operating margin | −18.7% | −7.4% (better) |
| Net margin | −25.7% | −6.1% (better) |
| FCF margin | −18.1% | 1.1% (better) |
| Return on equity | −779% | −4.9% (better) |
| Return on invested capital | −55.4% | −11.1% (better) |
| Financial health | ||
| Debt / equity | 5.43 | 0.02 (better) |
| Interest coverage | −2.5× (better) | −51.2× |
| Current ratio | 2.96 | 5.28 (better) |
| Altman Z-score | −6.23 | 6.67 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | −30.7% | – |
| Shareholder yield | −30.7% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 41.4% | 89.5% |
| Held by insiders | – | 1.9% |
| Insider net buying, 12 months | $3.0M (better) | −$18.1M |
| Short interest, % of float | – | 7.0% |
Go deeper
- BDSX stock overview
- BDSX income statement
- BDSX valuation and score
- CSTL stock overview
- CSTL income statement
- CSTL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.